PF-Atlas › Clinical Trials › NCT01100892
Cystic Fibrosis - Insulin Deficiency, Early Action
Once-daily insulin detemir · Phase 3
Registry ID
NCT01100892
Phase
Phase 3
Status
Completed
Drug / intervention
Once-daily insulin detemir
Sponsor
Sydney Children's Hospitals Network
Start
2010-12
Enrollment
100
Locations
6
About this trial
Cystic Fibrosis (CF) is the most common life-threatening genetic condition affecting Australian children. As well as repeated lung infections, children with CF develop insulin deficiency and eventually diabetes. The CF-IDEA trial (Cystic Fibrosis - Insulin Deficiency, Early Action) will determine whether starting insulin treatment before the onset of diabetes (earlier than current practice) will improve the health of children with CF by improving body weight and lung function.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01100892 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.